capivasertib,fulvestrant,AZD5363
astrazeneca,otsuka
['mbc', 'capivasertib', 'biomarker']
nice to see updated biomarker analysis from faktion showing pfs and os benefit for capivasertib + fulv in hr+ mbc is driven by pi3k pathway altered tumors - excited for capitello 291 &amp; more strategies targeting pi3k pathway alterations beyond pik3ca in mbc #asco22
Oncology fellow @uw_hemeoncpc - @UWMadison via @uchicagomstp | liquid biopsy biomarkers #bcsm | she/her ??????